Global Information Lookup Global Information

Rigosertib information


Rigosertib
Names
IUPAC name
(2-Methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethene-1-sulfonyl]methyl}phenyl)glycine
Systematic IUPAC name
(2-Methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethene-1-sulfonyl]methyl}anilino)acetate
Other names
ON-01910
Identifiers
CAS Number
  • 592542-59-1 checkY
3D model (JSmol)
  • [1]: Interactive image
ChEBI
  • CHEBI:145417
ChEMBL
  • ChEMBL1241855
  • ChEMBL2013119
ChemSpider
  • 5293927
IUPHAR/BPS
  • 7833
KEGG
  • D10154
PubChem CID
  • 6918736
UNII
  • 67DOW7F9GL checkY
CompTox Dashboard (EPA)
  • DTXSID30207984 Edit this at Wikidata
InChI
  • InChI=1S/C21H25NO8S/c1-27-15-10-19(29-3)16(20(11-15)30-4)7-8-31(25,26)13-14-5-6-18(28-2)17(9-14)22-12-21(23)24/h5-11,22H,12-13H2,1-4H3,(H,23,24)/b8-7+
    Key: OWBFCJROIKNMGD-BQYQJAHWSA-N
SMILES
  • [1]: COC1=C(C=C(C=C1)CS(=O)(=O)/C=C/C2=C(C=C(C=C2OC)OC)OC)NCC(=O)O
Properties
Chemical formula
C21H25NO8S
Molar mass 451.49 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Rigosertib (ON-01910 sodium salt, with Estybon as trade name) is a synthetic benzyl styryl sulfone in development by Onconova Therapeutics.[2] Rigosertib is in phase III clinical trials for the treatment of chronic myelomonocytic leukemia.[3]

Its geometrical isomer (Z)-ON 01910·Na has less cytotoxicity on cancer cells.

  1. ^ "physical and chemical data on chemispider website".
  2. ^ "Onconova Therapeutics". Retrieved 2019-04-26.
  3. ^ "Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients with Myelodysplastic Syndrome with Excess Blasts Progressing on or After Azacitidine or Decitabine". 29 June 2020.

and 2 Related for: Rigosertib information

Request time (Page generated in 0.5178 seconds.)

Rigosertib

Last Update:

Rigosertib (ON-01910 sodium salt, with Estybon as trade name) is a synthetic benzyl styryl sulfone in development by Onconova Therapeutics. Rigosertib...

Word Count : 146

PLK1

Last Update:

regression in NSCLC in vivo models treated with clinically relevant drugs. Rigosertib is an experimental RAS/PI3K/PLK1 inhibitor. PLK1 has been shown to interact...

Word Count : 1929

PDF Search Engine © AllGlobal.net